An Open-label Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment
Status:
Recruiting
Trial end date:
2022-11-03
Target enrollment:
Participant gender:
Summary
This is an open-label, single-dose study to evaluate the pharmacokinetics, pharmacodynamics
and safety of HSK7653 in subjects with mild, moderate, severe renal impairment and subjects
with kidney failure compared to the matched control subjects with normal renal function.